DOCSLIB.ORG

Combined Index to USP 40 and NF 35, Volumes 1–4

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Combined Index to USP 40 and NF 35, Volumes 1–4 Combined Index to USP 40 and NF 35 Abaca-Acety I-1 Combined Index to USP 40 and NF 35, Volumes 1±4 Page citations refer to the pages of Volumes 1, 2, 3, and 4 of USP 40±NF 35. This index is repeated in its entirety in each volume. 1±2526 Volume 1 2527±4740 Volume 2 4741±6778 Volume 3 6779±7969 Volume 4 Numbers in angle brackets such as 〈421〉 refer to chapter numbers in the General Chapters section. and (salts of) chlorpheniramine, Acetate A dextromethorphan, and methyl, 2370 pseudoephedrine, oral powder Acetate buffer, 2340 Abacavir containing at least three of the TS, 2411 oral solution, 2527 following, 2555 Acetazolamide, 2577 sulfate, 2531 and (salts of) chlorpheniramine, for injection, 2578 tablets, 2528 dextromethorphan, and oral suspension, 2579 and lamivudine tablets, 2529 pseudoephedrine, oral solution tablets, 2579 Abiraterone containing at least three of the Acetic acid, 2328, 7497 acetate, 2532 following, 2557 ammonium acetate buffer TS, 2412 acetate tablets, 2534 and (salts of) chlorpheniramine, diluted, 2328, 2353, 7497 Absolute dextromethorphan, and double-normal (2 N), 2424 alcohol, 2329 pseudoephedrine, tablets containing at glacial, 2328, 2361, 2580 ether, 2327 least three of the following, 2559 glacial, TS, 2412, 2415 Absorbable chlorpheniramine maleate, and and hydrocortisone otic solution, 4510 dusting powder, 3926 dextromethorphan hydrobromide irrigation, 2581 gelatin film, 4384 tablets, 2561 metaphosphoric, TS, 2418 gelatin sponge, 4384 and codeine phosphate capsules, 2563 otic solution, 2581 surgical suture, 6296 and codeine phosphate oral solution, 2564 strong, TS, 2412 Absorbent and codeine phosphate oral suspension, 1 M TS, 2411 cotton, 2327 2565 2 M TS, 2412 gauze, 4382 and codeine phosphate tablets, 2566 Acetic acid in peptides, 393 odorless paper, 2375 dextromethorphan hydrobromide, Acetic anhydride, 2328 Acacia, 7495 doxylamine succinate, and Acetohexamide, 2581 syrup, 7495 pseudoephedrine hydrochloride oral tablets, 2582 Acarbose, 2536 solution, 2567 Acetohydroxamic acid, 2582 Acebutolol hydrochloride, 2537 and diphenhydramine citrate tablets, 2569 tablets, 2583 capsules, 2538 diphenhydramine hydrochloride, and Acetone, 2328, 7498 Acepromazine maleate, 2540 pseudoephedrine hydrochloride tablets, anhydrous, 2328 injection, 2541 2570 buffered, TS, 2328, 2412, 2413 tablets, 2542 and hydrocodone bitartrate tablets, 4501 Acetonitrile, 2328 Acesulfame potassium, 7496 isometheptene mucate, and spectrophotometric, 2328 Acetal, 2327 dichloralphenazone capsules, 4692 Acetophenone, 2328 Acetaldehyde, 2327 and oxycodone capsules, 5516 p-Acetotoluidide, 2328 TS, 2411 and oxycodone tablets, 5517 Acetylacetone, 2328 Acetaminophen, 2542 and pentazocine tablets, 5625 Acetyl chloride, 2328 aspirin and caffeine tablets, 2550 and pseudoephedrine hydrochloride Acetylcholine chloride, 2328, 2584 and aspirin tablets, 2549 tablets, 2571 for ophthalmic solution, 2585 butalbital and caffeine capsules, 3090 oral solution, 2545 Acetylcysteine, 2586 butalbital and caffeine tablets, 3091 for effervescent oral solution, 2545 and isoproterenol hydrochloride inhalation and caffeine tablets, 2551 suppositories, 2546 solution, 2587 Index capsules, 2544 oral suspension, 2547 solution, 2586 and (salts of) chlorpheniramine, tablets, 2547 N-Acetylglucosamine, 6781 dextromethorphan, and extended-release tablets, 2548 3-Acetylthio-2-methylpropanoic acid, 2328 pseudoephedrine, capsules containing at and tramadol hydrochloride oral Acetyltributyl citrate, 7499 least three of the following, 2552 suspension, 6538 and tramadol hydrochloride tablets, 2572 Acetanilide, 2327 I-2 Acety-Alumi Combined Index to USP 40 and NF 35 Acetyltriethyl citrate, 7499 Polymyxin B sulfate and bacitracin zinc Alizarin complexone, 2330 N-Acetyltyrosine, 6782 topical, 5752 Alkaline N-Acetyl-L-tyrosine ethyl ester, 2329 Povidone±iodine topical, 5793 borate buffer, 2340 Acid Terbutaline sulfate inhalation, 6375 cupric citrate TS, 2412 acrylic, 2329 Thimerosal topical, 6439 cupric citrate TS 2, 2412 alpha lipoic, 7076 Tolnaftate topical, 6517 cupric iodide TS, 2412 dehydroacetic, 7630 Triamcinolone acetonide topical, 6559 cupric tartrate TS, 2412 ferric chloride TS, 2412 mercuric-potassium iodide TS, 2412 ferrous sulfate TS, 2412 phosphatase enzyme, 2330 iminodiacetic, 2365 picrate TS, 2412 stannous chloride TS, 2412 Agar, 2329, 7501 pyrogallol TS, 2420 stannous chloride TS, stronger, 2412 Agarose, 2329 sodium hydrosulfite TS, 2412 Acid-neutralizing capacity 〈301〉, 316 Air, medical, 2602 Alkyl (C12-15) benzoate, 7507 Acidulated phosphate and sodium fluoride Air-helium certified standard, 2329 Alkylphenoxypolyethoxyethanol, 2330 topical solution, 6190 Alanine, 2603 Allantoin, 2631 Acitretin, 2588 L-Alanyl-L-glutamine, 6784 Allopurinol, 2632 capsules, 2589 Albendazole, 2604 oral suspension, 2634 Acoustic emission 〈1005〉, 832 oral suspension, 2604 tablets, 2634 Acrylic acid, 2329 tablets, 2605 Allyl isothiocyanate, 2635 Activated Albumen TS, 2412 Almond oil, 7507 alumina, 2329 Albumin Almotriptan charcoal, 2329, 3344 bovine serum, 2329 tablets, 2638 magnesium silicate, 2329 human, 2606 Almotriptan malate, 2635 Acyclovir, 2591 rAlbumin human, 7502 Aloe, 2639 capsules, 2592 Albuterol, 2606 Alpha for injection, 2592 sulfate, 2611 lipoic acid, 7076 ointment, 2593 tablets, 2607 Alpha-chymotrypsin, 2330 oral suspension, 2594 extended-release tablets, 2608 Alpha cyclodextrin hydrate, 2330 tablets, 2595 Alclometasone dipropionate, 2612 Alpha-(2-(methylamino)ethyl)benzyl alcohol, Adamantane, 2329 cream, 2613 2330 Adapalene, 2596 ointment, 2614 Alphanaphthol, 2330 gel, 2598 Alcohol, 2329, 2615 Alphazurine 2G, 2407 Ademetionine disulfate tosylate, 6783 70 percent, 80 percent, and 90 percent, Alprazolam, 2641 Adenine, 2600 2329 oral suspension, 2642 sulfate, 2329 absolute, 2329 tablets, 2642 Adenosine, 2600 aldehyde-free, 2329 extended-release tablets, 2644 injection, 2601 alpha-(2-(methylamino)ethyl)benzyl, 2330 orally disintegrating tablets, 2648 Adipic acid, 2329, 7500 amyl, 2329 Alprenolol hydrochloride, 2330 Admissions tert-amyl, 2329, 2333, 2365 Alprostadil, 2649 to NF 35, 7483 butyl, 7544 injection, 2652 to USP 40, xxxiii dehydrated, 2329, 2349, 2616 Alteplase, 2652 Adulteration of dietary supplements with dehydrated isopropyl, 2329 for injection, 2655 drugs and drug analogs 〈2251〉, 2285 denaturated, 2329 Alternative microbiological sampling methods denaturated, TS, 2414 for nonsterile inhaled and nasal products determination 〈611〉, 503 〈610〉, 501 in dextrose injection, 2619 Altretamine, 2658 diluted, 2329, 7504 capsules, 2658 Aerosol injection, dehydrated, 2618 Alum, 2330 Bacitracin and polymyxin B sulfate topical, isobutyl, 2329 ammonium, 2330, 2659 2939 isopropyl, 2329 potassium, 2381, 2660 Benzocaine, butamben, and tetracaine methyl, 2329 Alumina, 2330 hydrochloride topical, 2979 neutralized, 2329, 2373 activated, 2329, 2330, 2333 Benzocaine and menthol topical, 2981 phenol TS, 2412 anhydrous, 2330 Benzocaine topical, 2970 n-propyl, 2330 aspirin, codeine phosphate, and magnesia Betamethasone dipropionate topical, 3005 rubbing, 2619 tablets, 2883 Dexamethasone sodium phosphate secondary butyl, 2330 aspirin, and magnesia tablets, 2877 inhalation, 3679 tertiary butyl, 2330 aspirin, and magnesium oxide tablets, Dexamethasone topical, 3671 Alcoholic 2878 Epinephrine bitartrate inhalation, 4002 ammonia TS, 2412 magnesia, and calcium carbonate Epinephrine inhalation, 3999 mercuric bromide TS, 2412 chewable tablets, 2663 Ergotamine tartrate inhalation, 4023 potassium hydroxide TS, 2412 magnesia, calcium carbonate, and Fluticasone propionate and salmeterol potassium hydroxide TS 2, 2420 simethicone chewable tablets, 2664 inhalation, 4303 TS, 2412 magnesia, and calcium carbonate oral Fluticasone propionate inhalation, 4288 Alcoholometric table, 2523 suspension, 2662 Inhalation and nasal drug products: Aldehyde dehydrogenase, 2330 magnesia, and simethicone oral aerosols, sprays, and powdersÐ Alendronate sodium, 2620 suspension, 2666 performance quality tests 〈601〉, 472 tablets, 2622 magnesia, and simethicone chewable Isoetharine mesylate inhalation, 4686 Alfadex, 7505 tablets, 2668 Isoproterenol hydrochloride inhalation, Alfentanil and magnesia oral suspension, 2660 4700 hydrochloride, 2623 and magnesia tablets, 2661 Index Isoproterenol hydrochloride and injection, 2624 magnesium carbonate, and magnesium phenylephrine bitartrate inhalation, 4702 Alfuzosin hydrochloride, 2625 oxide tablets, 2671 Isoproterenol sulfate inhalation, 4705 extended-release tablets, 2626 and magnesium carbonate oral suspension, Lidocaine topical, 4845 Alginates assay 〈311〉, 317 2669 Metaproterenol sulfate inhalation, 5040 Alginic acid, 7506 and magnesium carbonate tablets, 2670 Combined Index to USP 40 and NF 35 Alumi-Ammon I-3 Alumina (continued) Amifostine, 2709 Amitraz, 2756 and magnesium trisilicate oral suspension, for injection, 2710 concentrate for dip, 2757 2672 Amikacin, 2712 Amitriptyline hydrochloride, 2758 and magnesium trisilicate tablets, 2673 sulfate, 2713 and chlordiazepoxide tablets, 3358 Aluminon, 2330 sulfate injection, 2714 injection, 2759 Aluminum, 2330 Amiloride hydrochloride, 2714 and perphenazine tablets, 5652 acetate topical solution, 2674 and hydrochlorothiazide tablets, 2717 tablets, 2759 chloride, 2674 tablets, 2715 Amlodipine chlorohydrate, 2675 Amiloxate, 2719 oral suspension, 2760 chlorohydrate solution, 2676 Aminoacetic acid, 2331 and benazepril hydrochloride capsules, chlorohydrex polyethylene glycol, 2677 4-Aminoantipyrine, 2331 2761 chlorohydrex propylene glycol,
Load more

Recommended publications
  • Methyl Vinyl Ketone Mvk
    METHYL VINYL KETONE MVK CAUTIONARY RESPONSE INFORMATION 4. FIRE HAZARDS 7. SHIPPING INFORMATION 4.1 Flash Point: 30°F O.C. 20°F C.C. 7.1 Grades of Purity: 98.5+% Common Synonyms Liquid Colorless to light yellow Strong irritating 4.2 Flammable Limits in Air: 2.1% 15.6% 7.2 Storage Temperature: Cool ambient 3-Buten-2-one odor 4.3 Fire Extinguishing Agents: Dry 7.3 Inert Atmosphere: No requirement chemical, alcohol foam, carbon dioxide 7.4 Venting: Pressure-vacuum Mixes with water. Irritating vapor is produced. 4.4 Fire Extinguishing Agents Not to Be Used: Water may be ineffective. 7.5 IMO Pollution Category: Currently not available Evacuate. 4.5 Special Hazards of Combustion 7.6 Ship Type: Currently not available KEEP PEOPLE AWAY. AVOID CONTACT WITH LIQUID. Products: Not pertinent 7.7 Barge Hull Type: Currently not available Avoid inhalation. 4.6 Behavior in Fire: Vapor is heavier than Wear rubber overclothing (including gloves). air and may travel a considerable Shut off ignition sources. Call fire department. 8. HAZARD CLASSIFICATIONS distance to a source of ignition and flash Stay upwind. Use water spray to ``knock down'' vapor. back. At elevated temperatures (fire 8.1 49 CFR Category: Flammable liquid Notify local health and pollution control agencies. conditions) polymerization may take Protect water intakes. 8.2 49 CFR Class: 3 place in containers, causing violent 8.3 49 CFR Package Group: II rupture. Unburned vapors are very FLAMMABLE. irritating. 8.4 Marine Pollutant: No Fire Containers may explode in fire. 8.5 NFPA Hazard Classification: Flashback along vapor trail may occur.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • MDCT and Contrast Media: What Are the Risks?
    071_078_00_Thomsen:Thomsen 13-02-2008 9:32 Pagina 71 MDCT and Contrast Media: What are the Risks? Henrik S. Thomsen Department of Diagnostic Radiology, Copenhagen University Hospital Herlev, Herlev Department of Diagnostic Sciences, Faculty of Health Sciences, University of Copenhagen, Denmark Introduction Renal Adverse Reactions With the advent of multi-detector computed to- Contrast-material-induced kidney damage is imme- mography (MDCT) technology, the number of pa- diate, starting as soon as the first CM molecule reach- tients undergoing contrast-enhanced CT (CECT) es the kidney; however, it takes several hours or days studies has steadily grown in the last 6 years. In for a deterioration of renal function to be detected. 2005, approximately 22 million CECT examinations Despite more than 30 years of research, the patho- were carried out in the European Union, and 32 mil- physiology of CM-induced nephropathy (CIN) is lion in the United States (The Imaging Market Guide poorly elucidated. Nonetheless, several risk factors 2005. Arlington Medical Resources, Inc., Philadel- are well-known and can be divided into CM- and pa- phia, PA). Unfortunately, post-contrast-material-re- tient-related factors. lated adverse events, i.e., all those unintended and unfavorable signs, symptoms, or diseases temporally associated with the use of an iodinated contrast ma- Contrast-Medium-Related Factors terial (CM), are a common occurrence in radiology departments. Most adverse events occur within the More than 25 years ago, Barrett and Carlisle [1] first 60 min following CM administration (“imme- showed that the incidence of CIN is significantly diate” or “acute” adverse events), with the greatest higher after the administration of high-osmolarity risk in the first 20 min.
    [Show full text]
  • 01012100 Pure-Bred Horses 0 0 0 0 0 01012900 Lives Horses, Except
    AR BR UY Mercosu PY applied NCM Description applied applied applied r Final Comments tariff tariff tariff tariff Offer 01012100 Pure-bred horses 0 0 0 0 0 01012900 Lives horses, except pure-bred breeding 2 2 2 2 0 01013000 Asses, pure-bred breeding 4 4 4 4 4 01019000 Asses, except pure-bred breeding 4 4 4 4 4 01022110 Purebred breeding cattle, pregnant or lactating 0 0 0 0 0 01022190 Other pure-bred cattle, for breeding 0 0 0 0 0 Other bovine animals for breeding,pregnant or 01022911 lactating 2 2 2 2 0 01022919 Other bovine animals for breeding 2 2 2 2 4 01022990 Other live catlle 2 2 2 2 0 01023110 Pure-bred breeding buffalo, pregnant or lactating 0 0 0 0 0 01023190 Other pure-bred breeding buffalo 0 0 0 0 0 Other buffalo for breeding, ex. pure-bred or 01023911 pregnant 2 2 2 2 0 Other buffalo for breeding, except pure-bred 01023919 breeding 2 2 2 2 4 01023990 Other buffalos 2 2 2 2 0 01029000 Other live animals of bovine species 0 0 0 0 0 01031000 Pure-bred breedig swines 0 0 0 0 0 01039100 Other live swine, weighing less than 50 kg 2 2 2 2 0 01039200 Other live swine, weighing 50 kg or more 2 2 2 2 0 01041011 Pure-bred breeding, pregnant or lactating, sheep 0 0 0 0 0 01041019 Other pure-bred breeding sheep 0 0 0 0 0 01041090 Others live sheep 2 2 2 2 0 01042010 Pure-bred breeding goats 0 0 0 0 0 01042090 Other live goats 2 2 2 2 0 Fowls spec.gallus domestic.w<=185g pure-bred 01051110 breeding 0 0 0 0 0 Oth.live fowls spec.gall.domest.weig.not more than 01051190 185g 2 2 2 2 0 01051200 Live turkeys, weighing not more than 185g 2 2
    [Show full text]
  • Antiluteogenic Effects of Serial Prostaglandin F2α Administration in Mares
    ANTILUTEOGENIC EFFECTS OF SERIAL PROSTAGLANDIN F2α ADMINISTRATION IN MARES Thesis Presented in partial fulfillment of the requirements for the Master of Science in the Graduate School of The Ohio State University Elizabeth Ann Coffman Graduate ProGram in Comparative and Veterinary Medicine The Ohio State University 2013 Thesis committee: Carlos R.F. Pinto PhD, MV, DACT; Dissertation Advisor Marco A. Coutinho da Silva PhD, MV, DACT; Academic Advisor Christopher Premanandan PhD, DVM, DACVP Copyright by Elizabeth Ann Coffman 2013 Abstract For breedinG manaGement and estrus synchronization, prostaGlandin F2α (PGF) is one of the most commonly utilized hormones to pharmacologically manipulate the equine estrous cycle. There is a general supposition a sinGle dose of PGF does not consistently induce luteolysis in the equine corpus luteum (CL) until at least five to six days after ovulation. This leads to the erroneous assumption that the early CL (before day five after ovulation) is refractory to the luteolytic effects of PGF. An experiment was desiGned to test the hypotheses that serial administration of PGF in early diestrus would induce a return to estrus similar to mares treated with a sinGle injection in mid diestrus, and fertility of the induced estrus for the two treatment groups would not differ. The specific objectives of the study were to evaluate the effects of early diestrus treatment by: 1) assessing the luteal function as reflected by hormone profile for concentration of plasma progesterone; 2) determininG the duration of interovulatory and treatment to ovulation intervals; 3) comparing of the number of pregnant mares at 14 days post- ovulation. The study consisted of a balanced crossover desiGn in which reproductively normal Quarter horse mares (n=10) were exposed to two treatments ii on consecutive reproductive cycles.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Selling Mercury Cosmetics and Pharmaceuticals (W-Hw4-22)
    www.pca.state.mn.us Selling mercury cosmetics and pharmaceuticals Mercury-containing skin lightening creams, lotions, soaps, ointments, lozenges, pharmaceuticals and antiseptics Mercury is a toxic element that was historically used in some cosmetic, pharmaceutical, and antiseptic products due to its unique properties and is now being phased out of most uses. The offer, sale, or distribution of mercury-containing products is regulated in Minnesota by the Minnesota Pollution Control Agency (MPCA). Anyone offering a mercury-containing product for sale or donation in Minnesota is subject to these requirements, whether a private citizen, collector, non-profit organization, or business. Offers and sales through any method are regulated, whether in a store or shop, classified advertisement, flea market, or online. If a mercury-containing product is located in Minnesota, it is regulated, regardless of where a purchaser is located. Note: This fact sheet discusses the requirements and restrictions of the MPCA. Cosmetics and pharmaceuticals may also be regulated for sale whether they contain mercury or not by other state or federal agencies, including the Minnesota Board of Pharmacy and the U.S. Food & Drug Administration. See More information on page 2. What are the risks of using mercury-containing products? Use of mercury-containing products can damage the brain, kidneys, and liver. Children and pregnant women are at increased risk. For more information about the risks of mercury exposure, visit the Minnesota Department of Health. See More information on the page 2. If you believe you have been exposed to a mercury-containing product, contact your health care provider or the Minnesota Poison Control Center at 1-800-222-1222.
    [Show full text]
  • Pdf; Chi 2015 DPP Air in Cars.Pdf; Dodson 2014 DPP Dust CA.Pdf; Kasper-Sonnenberg 2014 Phth Metabolites.Pdf; EU Cosmetics Regs 2009.Pdf
    Bouge, Cathy (ECY) From: Nancy Uding <[email protected]> Sent: Friday, January 13, 2017 10:24 AM To: Steward, Kara (ECY) Cc: Erika Schreder Subject: Comments re. 2016 CSPA Rule Update - DPP Attachments: DPP 131-18-0 exposure.pdf; Chi 2015 DPP air in cars.pdf; Dodson 2014 DPP dust CA.pdf; Kasper-Sonnenberg 2014 phth metabolites.pdf; EU Cosmetics Regs 2009.pdf Please accept these comments from Toxic-Free Future concerning the exposure potential of DPP for consideration during the 2016 CSPA Rule update. Regards, Nancy Uding -- Nancy Uding Grants & Research Specialist Toxic-Free Future 206-632-1545 ext.123 http://toxicfreefuture.org 1 JES-00888; No of Pages 9 JOURNAL OF ENVIRONMENTAL SCIENCES XX (2016) XXX– XXX Available online at www.sciencedirect.com ScienceDirect www.elsevier.com/locate/jes Determination of 15 phthalate esters in air by gas-phase and particle-phase simultaneous sampling Chenchen Chi1, Meng Xia1, Chen Zhou1, Xueqing Wang1,2, Mili Weng1,3, Xueyou Shen1,4,⁎ 1. College of Environmental & Resource Sciences, Zhejiang University, Hangzhou 310058, China 2. Zhejiang National Radiation Environmental Technology Co., Ltd., Hangzhou 310011, China 3. School of Environmental and Resource Sciences, Zhejiang Agriculture and Forestry University, Hangzhou 310058, China 4. Zhejiang Provincial Key Laboratory of Organic Pollution Process and Control, Hangzhou 310058, China ARTICLE INFO ABSTRACT Article history: Based on previous research, the sampling and analysis methods for phthalate esters (PAEs) Received 24 December 2015 were improved by increasing the sampling flow of indoor air from 1 to 4 L/min, shortening the Revised 14 January 2016 sampling duration from 8 to 2 hr.
    [Show full text]
  • Medication List
    Medication List Walgreens Plus™ members receive discounts on thousands of generic and brand-name medications included on this Medication List, which is divided into two sections, “Value Priced” Medications and “Discounted” Medications*. The price for a medication identified as “Value-Priced” is listed below: Get savings up to 85% off Cash Prices • 30-day-supply drugs cost $5 (tier 1), $10 (tier 2) or $15 (tier 3) on Atorvastatin (generic Lipitor) and • 90-day-supply drugs cost $10 (tier 1), $20 (tier 2) or $30 (tier 3) Rosuvastatin (generic Crestor) †† The Discounted Medications section lists the discounts offered to Walgreens Plus members on other generic and brand-name medications not included in the Value-Priced Medication section. The price for a medication is based on its tier and whether it is a 30-day or 90-day supply†. There may be an additional cost for quanities greater than those listed. This discount prescription pricing applies only to Walgreen Plus members on prescriptions purchased in select Walgreens stores that are not billed to insurance and/or used in combination with other health or pharmacy benefit programs. For further details, see your pharmacist or Walgreens.com/Plus. VALUE GENERICS NAPROXEN 250MG TAB 2 60 180 Antifungal NAPROXEN 500MG TAB 2 60 180 Quantity NAPROXEN 375MG TAB 2 60 180 Drug Name Tier 30 90 NAPROXEN DR 500MG TAB 3 60 180 FLUCONAZOLE 150MG TAB 2 1 3 TERBINAFINE 250MG TAB 2 30 90 Asthma Quantity Antiviral Drug Name Tier 30 90 Quantity ALBUTEROL 0.083% INH SOLN 25X3ML 2 75 225 Drug Name Tier 30 90 AMINOPHYLLINE
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Antibiotic Use Guidelines for Companion Animal Practice (2Nd Edition) Iii
    ii Antibiotic Use Guidelines for Companion Animal Practice (2nd edition) iii Antibiotic Use Guidelines for Companion Animal Practice, 2nd edition Publisher: Companion Animal Group, Danish Veterinary Association, Peter Bangs Vej 30, 2000 Frederiksberg Authors of the guidelines: Lisbeth Rem Jessen (University of Copenhagen) Peter Damborg (University of Copenhagen) Anette Spohr (Evidensia Faxe Animal Hospital) Sandra Goericke-Pesch (University of Veterinary Medicine, Hannover) Rebecca Langhorn (University of Copenhagen) Geoffrey Houser (University of Copenhagen) Jakob Willesen (University of Copenhagen) Mette Schjærff (University of Copenhagen) Thomas Eriksen (University of Copenhagen) Tina Møller Sørensen (University of Copenhagen) Vibeke Frøkjær Jensen (DTU-VET) Flemming Obling (Greve) Luca Guardabassi (University of Copenhagen) Reproduction of extracts from these guidelines is only permitted in accordance with the agreement between the Ministry of Education and Copy-Dan. Danish copyright law restricts all other use without written permission of the publisher. Exception is granted for short excerpts for review purposes. iv Foreword The first edition of the Antibiotic Use Guidelines for Companion Animal Practice was published in autumn of 2012. The aim of the guidelines was to prevent increased antibiotic resistance. A questionnaire circulated to Danish veterinarians in 2015 (Jessen et al., DVT 10, 2016) indicated that the guidelines were well received, and particularly that active users had followed the recommendations. Despite a positive reception and the results of this survey, the actual quantity of antibiotics used is probably a better indicator of the effect of the first guidelines. Chapter two of these updated guidelines therefore details the pattern of developments in antibiotic use, as reported in DANMAP 2016 (www.danmap.org).
    [Show full text]
  • Pharmacologyonline 2: 727-753 (2010) Ewsletter Bradu and Rossini
    Pharmacologyonline 2: 727-753 (2010) ewsletter Bradu and Rossini COTRAST AGETS - IODIATED PRODUCTS. SECOD WHO-ITA / ITA-OMS 2010 COTRIBUTIO O AGGREGATE WHO SYSTEM-ORGA CLASS DISORDERS AD/OR CLUSTERIG BASED O REPORTED ADVERSE REACTIOS/EVETS Dan Bradu and Luigi Rossini* Servizio Nazionale Collaborativo WHO-ITA / ITA-OMS, Università Politecnica delle Marche e Progetto di Farmacotossicovigilanza, Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona, Regione Marche, Italia Summary From the 2010 total basic adverse reactions and events collected as ADRs preferred names in the WHO-Uppsala Drug Monitoring Programme, subdivided in its first two twenty years periods as for the first seven iodinated products diagnostic contrast agents amidotrizoate, iodamide, iotalamate, iodoxamate, ioxaglate, iohexsol and iopamidol, their 30 WHO-system organ class disorders (SOCDs) aggregates had been compared. Their common maximum 97% levels identified six SOCDs only, apt to evaluate the most frequent single ADRs for each class, and their percentual normalization profiles for each product. The WILKS's chi square statistics for the related contingency tables, and Gabriel’s STP procedure applied to the extracted double data sets then produced profile binary clustering, as well as Euclidean confirmatory plots. They finally showed similar objectively evaluated autoclassificative trends of these products, which do not completely correspond to their actual ATC V08A A, B and C subdivision: while amidotrizoate and iotalamate, and respectively iohesol and iopamidol are confirmed to belong to the A and B subgroups, ioxaglate behaves fluctuating within A, B and C, but iodamide looks surprizingly, constantly positioned together with iodoxamate as binary/ternary C associated. In view of the recent work of Campillos et al (Science, 2008) which throws light on the subject, the above discrepancies do not appear anymore unexpected or alarming.
    [Show full text]